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Arginine-dependent cancers represent a significant 
fraction of malignancies characterized by loss of urea-
cycle enzymes, especially argininosuccinate synthetase 
(ASS1) and argininosuccinate lyase (ASL). As a tumor 
suppressor ASS1 catalyzes the condensation of aspartate 
and citrulline into argininosuccinate, and impacts multiple 
biological pathways involving arginine either directly, for 
instance via nitric oxide or mTOR, or indirectly, such as 
modulation of nucleotide synthesis [1, 2]. Loss of ASS1 
promotes increased tumor cell proliferation and invasion, 
and is immunosuppressive, all attributes of a highly 
tumorigenic cancer [3, 4]. ASS1 deficiency has been 
identified across the spectrum of haematological, epithelial 
and mesenchymal tumors, however regulation and 
expression of the enzyme displays significant variability 
and is tissue-specific. This is most evident under arginine 
withdrawal, which has been explored for several decades 
as a novel metabolic anticancer therapy targeting the 
arginine-dependent phenotype. Methylation-dependent 
silencing of the ASS1 promoter reported in mesothelioma 
and bladder cancer cell lines confers exquisite sensitivity 
to the arginine-lowering agents, arginine deiminase or 
arginase. In contrast, ASS1 is induced rapidly in tumor 
cell lines without ASS1 promoter methylation limiting 
the applicability of arginine deprivation under these 
circumstances, particularly as a monotherapy. ASL, which 
is downstream of ASS1 and converts argininosuccinate 
into arginine and fumarate, has a secondary role in 
modulating tumoral arginine auxotrophy and sensitivity 
to arginine depletors in cancers including glioblastoma 
multiforme [5].
Arginine deprivation entered the clinic over a 
decade ago with pegylated arginine deiminase (ADI-
PEG 20), which catalyzes the conversion of arginine into 
citrulline and ammonia, thereby recycling the former into 
arginine in ASS1 competent cells. Several monotherapy 
cancer studies of ADI-PEG 20 revealed safety and 
promising early activity despite the antigenic properties of 
a mycoplasma-derived enzyme. However, a recent phase 
3 study of ADI-PEG 20 versus placebo in patients with 
post-sorafenib relapse in liver cancer was negative for 
overall survival. Post-hoc analyses revealed that ASS1 was 
upregulated by sorafenib and may have influenced patient 
outcome (clinicaltrial.gov identifier NCT01287585). 
In contrast, a modest improvement in progression-free 
survival in a randomized phase 2 study in patients with 
ASS1-deficient mesothelioma versus best supportive 
care alone was reported in the ADAM trial highlighting 
a need for patient selection in future studies [6]. Early 
phase clinical studies of several non-antigenic pegylated-
arginases are underway and further testing will reveal how 
the differential catalysis of arginine into ornithine and urea 
will impact tumorigenesis.
In addition to ASS1 selection several groups have 
used molecular imaging to investigate responses to ADI-
PEG 20. The increased glycolytic activity of neoplastic 
cells (Warburg effect) led to the development of fluoro-
2-deoxy-D-glucose positron emission tomography 
(FDG-PET/CT). Early metabolic responses with FDG-
PET/CT to arginine depletion have been evaluated in 
the ADAM trial for mesothelioma using EORTC based 
recommendations for change in standardized uptake value 
(SUVmax) to define the response categories (progression 
(PD)> 25% increase and partial metabolic response (PMR) 
>15% decrease in SUVmax). Whilst no modified RECIST 
partial or complete responses were observed during the 
study, FDG-PET/CT revealed a PMR in 46%; stable 
disease in 31%; a mixed response in 8% and progressive 
disease (PD) in 15% of patients [6]. However, ADI-PEG 
20-induced arginine deprivation is known to increase 
serine biosynthesis, glutamine anaplerosis, oxidative 
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Figure 1: Emerging resistance to arginine deprivation 
in cancer. Several mechanisms may reduce the efficacy 
of arginine depleting enzymes for cancer therapy: (1) ASS1 
upregulation; (2) autophagy; (3) stromal-tumor cell metabolic 
co-operation; (4) and anti-drug antibodies (e.g. to ADI-PEG 20). 
Some approaches to overcoming resistance include combining 
arginine depletors with chemotherapy, human (non-antigenic) 
arginases, and autophagy modulators such as chloroquine.
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phosphorylation, and decrease aerobic glycolysis, 
effectively inhibiting the Warburg effect, thereby limiting 
the wider applicability of FDG-PET/CT [7]. The reduction 
of glycolysis in cells otherwise dependent on aerobic 
glycolysis is correlated with reduced PKM2 expression 
and phosphorylation and upregulation of phosphoglycerate 
dehydrogenase (PHGDH). Recent work has investigated 
fluoro-3’-deoxythymidine (FLT)-PET/CT, a proliferation 
surrogate, as a potentially more robust response biomarker 
to arginine deprivation therapy, which overcomes the 
pitfalls of FDG-PET/CT. In preclinical studies, it has been 
shown that the combination of arginine deprivation and 
pemetrexed leads to a potentiation of cytotoxicity in ASS1-
negative tumor cells and is accompanied by suppression 
of de novo thymidine synthesis with decreased levels of 
thymidylate synthase and the salvage pathway via reduced 
thymidine kinase 1 [3]. Recent clinical work shows an 
early and end of treatment response on FLT PET/CT, 
which is at least as good as RECIST response. Indeed, 
early phase combination trials of arginine deprivation 
with chemotherapy are reporting increased efficacy, and 
sustained arginine depletion with reduced immunogenicity 
of ADI-PEG 20 [8]. In thoracic cancers this multimodality 
strategy has instigated the phase 2/3 ATOMIC-meso 
trial of pemetrexed and cisplatin with or without ADI-
PEG 20 focusing on chemorefractory (non-epithelioid) 
mesotheliomas.
Lastly, further optimization of arginine deprivation 
for cancer therapy may be achieved with modulation 
of key resistance pathways (Figure 1). As noted 
upregulation of ASS1 is a significant limitation with a 
potentially narrow therapeutic index for pharmacological 
intervention, and is also variable across tumors studied 
to date. On the other hand blocking autophagy, or the 
cellular recycling of organelles and macromolecules via 
lysosomal degradation - which provides an alternative 
but finite source of arginine - may be more tractable 
using existing quinoline-based anti-malarials. Finally, the 
stromal compartment of tumors is also a potential source 
of arginine flux that may modulate the efficacy of arginine 
deprivation in the clinic. Thus, as our understanding of 
the arginine metabolome in tumorigenesis increases, it 
is hoped that further refinements of arginine degrading 
therapies, will translate to improved outcomes for patients 
with currently intractable cancers.
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